CoChat

Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database

Open access
Ruggiero, Rosanna, Mascolo, Annamaria, Spezzaferri, Angela, Carpentieri, Claudia, Torella, Daniele, Sportiello, Liberata, Rossi, Francesco, Paolisso, Giuseppe, Capuano, Annalisa · 2024 · Pharmaceuticals
Cited by 55

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Background: A potential risk of suicide associated with liraglutide or semaglutide treatments has recently emerged. Therefore, we decided to investigate the reporting probability of suicidal events among glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Methods: A retrospective pharmacovigilance study of the European Pharmacovigilance database was conducted for the period from 1 January 2018 to 10 July 2023. Disproportionality analyses (reporting odds ratio, ROR) were performed to assess the reporting probability of suicidal events among GLP-1 RAs. Results: A total of 230 reports of suicidal events were identified. The most reported GLP-1 RA was liraglutide (38.3%), followed by semaglutide (36.5%) and dulaglutide (16.1%). The most reported events were suicidal ideation (65.3%) and suicide attempt (19.5%). Disproportionality analysis found a higher reporting probability of suicidal events for semaglutide than dulaglutide (ROR, 2.05; 95%CI, 1.40–3.01) and exenatide (ROR, 1.81; 95%CI, 1.08–3.05). In the same way, liraglutide was associated with a higher reporting probability of suicidal events than dulaglutide (ROR, 3.98; 95%CI, 2.73–5.82) and exenatide (ROR, 3.52; 95%CI, 2.10–5.92). On the contrary, a lower reporting probability was found for semaglutide than liraglutide (ROR, 0.51; 95%CI, 0.38–0.69). Conclusions: Suicidal events were mostly reported with semaglutide and liraglutide, which were also associated with significantly higher reporting probabilities compared to other GLP1 RAs. Although this study provides the reporting frequencies of suicide-related events with GLP-1 RAs, establishing causality requires further investigation, which will probably be addressed by the Pharmacovigilance Risk Assessment Committee of the European Medicine Agency in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph17020147

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 33

  1. Romera, 2022, Glucagon-like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations, Diabetes Ther., 13, 389, 10.1007/s13300-021-01198-5 · DOI
  2. Chiappini, S., Vickers-Smith, R., Harris, D., Pelletier, G.D.P., Corkery, J.M., Guirguis, A., Martinotti, G., Sensi, S.L., and Schifano, F. (2023). Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset. Pharmaceuticals, 16. · DOI
  3. Chen, 2023, Postmarket Safety Profile of Suicide/Self-Injury for GLP-1 Receptor Agonist: A Real-World Pharmacovigilance Analysis, Eur. Psychiatry, 66, e99, 10.1192/j.eurpsy.2023.2474 · DOI · Paper page
  4. Lucas, S., Ailani, J., Smith, T.R., Abdrabboh, A., Xue, F., and Navetta, M.S. (2022). Pharmacovigilance: Reporting Requirements throughout a Product’s Lifecycle. Ther. Adv. Drug Saf., 13. · DOI
  5. Kang, 2012, Anti-Obesity Drugs: A Review about Their Effects and Safety, Diabetes Metab. J., 36, 13, 10.4093/dmj.2012.36.1.13 · DOI · Paper page
  6. Rodgers, 2012, Anti-Obesity Drugs: Past, Present and Future, Dis. Model. Mech., 5, 621, 10.1242/dmm.009621 · DOI · Paper page
  7. Blonde, 2009, The Safety and Efficacy of Liraglutide with or without Oral Antidiabetic Drug Therapy in Type 2 Diabetes: An Overview of the LEAD 1-5 Studies, Diabetes Obes. Metab., 11, 26, 10.1111/j.1463-1326.2009.01075.x · DOI · Paper page
  8. Wisłowska-Stanek, A., Kołosowska, K., and Maciejak, P. (2021). Neurobiological Basis of Increased Risk for Suicidal Behaviour. Cells, 10. · DOI · Paper page
  9. Anderberg, 2017, Glucagon-like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight, Diabetes, 66, 1062, 10.2337/db16-0755 · DOI · Paper page
  10. Chivite, 2021, Central Serotonin Participates in the Anorexigenic Effect of GLP-1 in Rainbow Trout (Oncorhynchus mykiss), Gen. Comp. Endocrinol., 304, 113716, 10.1016/j.ygcen.2021.113716 · DOI
  11. Rossi, C., Ruggiero, R., Sportiello, L., Pentella, C., Gaio, M., Pinto, A., and Rafaniello, C. (2022). Did the COVID-19 Pandemic Affect Contrast Media-Induced Adverse Drug Reaction’s Reporting? A Pharmacovigilance Study in Southern Italy. J. Clin. Med., 11. · DOI
  12. Ruggiero, 2022, Capillary Leak Syndrome Following COVID-19 Vaccination: Data from the European Pharmacovigilance Database Eudravigilance, Front. Immunol., 13, 956825, 10.3389/fimmu.2022.956825 · DOI
  13. Sher, 2023, Suicide: An Overview for Clinicians, Med. Clin. N. Am., 107, 119, 10.1016/j.mcna.2022.03.008 · DOI
  14. Iwatate, 2023, Association of Obesity, Suicide Behaviors, and Psychosocial Wellness Among Adolescents in the United States, J. Adolesc. Health, 72, 526, 10.1016/j.jadohealth.2022.11.240 · DOI
  15. Sarkar, 2014, Diabetes Mellitus and Suicide, Indian. J. Endocrinol. Metab., 18, 468, 10.4103/2230-8210.137487 · DOI
  16. Conti, 2017, Clinical Characteristics of Diabetes Mellitus and Suicide Risk, Front. Psychiatry, 8, 248999, 10.3389/fpsyt.2017.00040 · DOI
  17. Amiri, 2018, Body Mass Index and Risk of Suicide: A Systematic Review and Meta-Analysis, J. Affect. Disord., 238, 615, 10.1016/j.jad.2018.05.028 · DOI · Paper page
  18. Klinitzke, 2013, Obesity and Suicide Risk in Adults—A Systematic Review, J. Affect. Disord., 145, 277, 10.1016/j.jad.2012.07.010 · DOI
  19. Branco, 2016, Association between Obesity and Suicide in Woman, but Not in Man: A Population-Based Study of Young Adults, Psychol. Health Med., 22, 275, 10.1080/13548506.2016.1164870 · DOI
  20. Ju, Y.J., Han, K.T., Lee, T.H., Kim, W., Park, J.H., and Park, E.C. (2016). Association between Weight Control Failure and Suicidal Ideation in Overweight and Obese Adults: A Cross-Sectional Study. BMC Public. Health, 16. · DOI
  21. Klein, 2021, Suicidality Risk of Newer Antiseizure Medications: A Meta-Analysis, JAMA Neurol., 78, 1118, 10.1001/jamaneurol.2021.2480 · DOI
  22. Mula, 2013, Antiepileptic Drugs and Suicidality: An Expert Consensus Statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology, Epilepsia, 54, 199, 10.1111/j.1528-1167.2012.03688.x · DOI · Paper page
  23. Bell, 2009, Suicidality in People Taking Antiepileptic Drugs What Is the Evidence?, CNS Drugs, 23, 281, 10.2165/00023210-200923040-00002 · DOI
  24. Mula, 2022, Suicidality and Antiepileptic Drugs in People with Epilepsy: An Update, Expert Rev. Neurother., 22, 405, 10.1080/14737175.2022.2064744 · DOI
  25. Pop, G., Farcaș, A., Butucă, A., Morgovan, C., Arseniu, A.M., Pumnea, M., Teodoru, M., and Gligor, F.G. (2022). Post-Marketing Surveillance of Statins—A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance. Pharmaceuticals, 15. · DOI
  26. Fong, 2022, Association of Suicidal Ideation and Depression with the Use of Proton Pump Inhibitors in Adults: A Cross-Sectional Study, Sci. Rep., 12, 19539, 10.1038/s41598-022-24244-z · DOI
  27. Mamdani, 2019, Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide, JAMA Netw. Open, 2, e1913304, 10.1001/jamanetworkopen.2019.13304 · doi:10.1001/jamanetworkopen.2019.13304
  28. Herdeiro, 2005, Physicians’ Attitudes and Adverse Drug Reaction Reporting A Case-Control Study in Portugal, Drug Saf., 28, 825, 10.2165/00002018-200528090-00007 · DOI · Paper page
  29. Herdeiro, 2009, Determinants of Under-Reporting of Adverse Drug Reactions A Systematic Review, Drug Saf., 32, 19, 10.2165/00002018-200932010-00002 · DOI · Paper page
  30. Costa, 2023, Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: A Systematic Review Update, Drug Saf., 46, 625, 10.1007/s40264-023-01302-7 · DOI
  31. Goldman, 1998, Limitations and Strengths of Spontaneous Reports Data, Clin. Ther., 20, C40, 10.1016/S0149-2918(98)80007-6 · DOI · Paper page
  32. Ferrajolo, 2014, Pediatric Drug Safety Surveillance in Italian Pharmacovigilance Network: An Overview of Adverse Drug Reactions in the Years 2001–2012, Expert Opin. Drug Saf., 13, 939581, 10.1517/14740338.2014.939581 · DOI
  33. Ferrajolo, C., Arcoraci, V., Sullo, M.G., Rafaniello, C., Sportiello, L., Ferrara, R., Cannata, A., Pagliaro, C., Tari, M.G., and Patrizio Caputi, A. (2014). Pattern of Statin Use in Southern Italian Primary Care: Can Prescription Databases Be Used for Monitoring Long-Term Adherence to the Treatment?. PLoS ONE, 9. · DOI

Cited by

Metadata

Authors
Ruggiero, R., Mascolo, A., Spezzaferri, A., Carpentieri, C., Torella, D., Sportiello, L., Rossi, F., Paolisso, G., & Capuano, A.
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2024-01-23
Volume
17
Issue
2
Pages
147
ISSN
1424-8247 (ISSN-L)
OpenAlex
W4391141493
Cited by
55
References
10
FWCI
41.41
Type
journal article
Language
en
Open access
gold
Funders
Italian Medicine Agency (AIFA) (B61G17000170005)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.